Summary

A randomized, open-label Phase 2 trial with patients who had small cell lung cancer (SCLC) that had progressed during or after first-line platinum-based chemotherapy found no significant difference in progression-free survival with cabazitaxel against topotecan, the current standard for comparison [Riemsma R et al. BMC Cancer 2010]. The median overall survival was shorter for patients taking cabazitaxel versus those taking topotecan [NCT01500720].